<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02415556</url>
  </required_header>
  <id_info>
    <org_study_id>2015P000064</org_study_id>
    <secondary_id>1R01DK103902-01A1</secondary_id>
    <nct_id>NCT02415556</nct_id>
  </id_info>
  <brief_title>Memory Aid by Intranasal Insulin in Diabetes (MemAID)</brief_title>
  <acronym>MemAID</acronym>
  <official_title>Memory Advancement by Intranasal Insulin in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to find the long-term effects of daily administration of 40
      IU of intranasal insulin (INI) as compared to placebo (sterile saline) on cognition and
      memory in people with type 2 diabetes mellitus (DM), and non-diabetic controls over 24 weeks
      with a follow-up period for 24 weeks. Four groups will be tested: DM group treated with INI;
      DM group treated with placebo; control group treated with INI and the control group treated
      with placebo. The INI or placebo will be delivered into the nose. The investigators are
      interested to see whether INI can improve memory and cognition and blood flow in the brain in
      the type 2 DM group as compared to placebo and to the non-diabetic group over a long-term
      period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a randomized controlled trial determining the long-term effects of
      intranasal insulin (INI) on cognition and memory in type 2 diabetes (DM) and non-DM groups.
      The investigators hypothesize that: 1) INI-treated adults with DM have better memory and
      functioning of specific cognitive domains and faster walking during a dual task than those
      treated with placebo and the control group; 2) Glycemic and insulin resistance and genetic
      markers for Alzheimer's disease (Apolipoprotein E4 [ApoE4]) may serve as predictors of
      positive responses to INI therapy; 3) INI treatment neither adversely affects systemic
      glycemic levels or the cardiovascular system nor causes weight gain.

      Aim 1: To determine whether INI-treated type 2 DM adults have a) better memory and
      functioning of specific cognitive domains and b) faster dual-task gait speed and better daily
      living functioning than the placebo-treated and non-DM groups. Four groups will be tested: 60
      DM subjects treated with insulin; 60 DM subjects treated with placebo; 45 control subjects
      treated with INI and 45 control subjects treated with placebo. These 210 patients are
      expected to complete treatment and 168 are expected to complete study by the study completion
      anticipated date.

      The investigators will conduct a randomized, double-blind, placebo-controlled study in 120
      older adults with type 2 DM and 90 non-DM controls examining whether 40 IU INI once daily
      over a 24-week period improves:

        -  Specific domains of visuospatial attention and memory, verbal learning (primary
           outcomes);

        -  Gait speed during a dual task (which is an excellent predictor of overall health), daily
           living functionality, and depression as compared to the DM group receiving sterile
           saline and the non-DM groups. The non-DM groups will provide reference of INI effects in
           a clinical phenotype of cognitive decline and insulin resistance that occurs with normal
           aging.

      Aim 2: To identify a phenotype and long-term trajectory predicting clinically relevant
      response to INI therapy based on glycemic control, insulin resistance, endothelial and
      genetic markers.

        1. The investigators will determine a phenotype predicting a clinically relevant response
           to INI therapy and identify time-dependent trajectories of INI effects on cognition in
           the DM group vs. the placebo and the non-DM groups. Clinical predictors will be based on
           associations between cognitive function and/or gait and demographic, glycemic control,
           insulin resistance, endothelial and genetic (ApoE4) measures.

        2. The investigators will evaluate the dose-escalating trajectory of cognition, gait speed,
           and functionality during the 24 weeks of therapy and 24 weeks post-treatment and their
           dependence on the above-mentioned factors, and determine the time point when maximum
           effect was reached. INI therapy response is defined as a clinically relevant improvement
           on cognitive tests or in gait speed (as a continuous variable) or as responders vs.
           non-responders as compared to placebo within DM and non-DM groups (as a categorical
           variable).

        3. MRI substudy: The investigators will explore the long-term INI effects on regional
           perfusion, vasodilatation, and resting functional connectivity in 40 DM subjects pre-
           and post- INI/placebo administration at the beginning and at the end of intervention and
           their relationships to cognitive outcomes. Regional perfusion and vasodilatation will be
           measured by pseudo-continuous arterial spin labeling (PCASL) MRI at 3 Tesla, and
           resting-state functional connectivity will be quantified from low-frequency (0.01-0.08
           Hz) fluctuations (LFF) of the whole-brain blood-oxygen-level dependent (BOLD) functional
           Magnetic Resonance Imaging (fMRI).

      Aim 3: To determine the long-term safety of INI vs. placebo with regard to glycemic control
      (fasting glucose, hemoglobin A1c [HbA1c], hypoglycemic episodes), vital signs, and body mass.

        1. The investigators will obtain measurements of fasting glucose, insulin, vital signs, and
           body mass at baseline, 2-months, 4-months, and 6-months follow-up and keep weekly logs
           monitoring glucose and adverse events.

        2. Safety substudy: In the first 20 DM patients treated with subcutaneous insulin, the
           investigators will conduct continuous glucose monitoring (CGM) OR 5 finger sticks/day
           (effective after 9/25/2017) for 1 week during baseline and during the first week of INI
           or placebo treatment to evaluate the INI effects on glycemic control, hypoglycemic
           episodes, and body weight.

      This study may pave the way to potential treatment and/or cure of DM- and age-related
      cognitive decline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>120 T2DM adults and 90 non-DM controls (as of 9/25/2017)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Paired Associates Learning (PAL) total errors (adjusted)</measure>
    <time_frame>Measured at weeks: 1 (twice, before and after intervention), 8, 16, 24, 25 (last intervention), 32, 40, 48 (last follow-up)</time_frame>
    <description>Visuospatial learning and memory - Difference between controls and diabetics at each time point</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Gait Speed</measure>
    <time_frame>Measured at weeks: 1 (twice, before and after intervention), 8, 16, 24, 25 (last intervention), 32, 40, 48 (last follow-up)</time_frame>
    <description>Visuospatial learning and memory - The difference between the average of baseline and intervention 1 and each subsequent time point</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fasting glucose</measure>
    <time_frame>Measured at screening and at weeks: 1-17, 19, 22, 24, 25 (last intervention), 32, 40, 48 (last follow-up)</time_frame>
    <description>Safety outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging (MRI) (Vasoreactivity) - for 40 DM patients only</measure>
    <time_frame>At weeks: 1 (twice, before and after intervention) and 24</time_frame>
    <description>vasodilatation will be measured by pseudo-continuous arterial spin labeling (PCASL) MRI at 3 Tesla</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic episodes</measure>
    <time_frame>At weeks: 1-25 (last intervention), 32, 40, 48 (last follow-up)</time_frame>
    <description>Safety outcome</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Type 2 Diabetes Mellitus - Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 IU of regular human insulin once daily over 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 Diabetes Mellitus - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intranasal sterile saline once daily over 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 IU of regular human insulin once daily over 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intranasal sterile saline once daily over 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular Human Insulin</intervention_name>
    <description>Regular human insulin 40 IU daily over 24 weeks</description>
    <arm_group_label>Type 2 Diabetes Mellitus - Insulin</arm_group_label>
    <arm_group_label>Control - Insulin</arm_group_label>
    <other_name>Novolin R Novonordisk</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intranasal sterile saline 40 IU daily over 24 weeks</description>
    <arm_group_label>Type 2 Diabetes Mellitus - Placebo</arm_group_label>
    <arm_group_label>Control - Placebo</arm_group_label>
    <other_name>Sterile normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 50-85 years old

          -  Able to walk for 6 minutes

          -  Diabetes type 2 (DM) group: diagnosis and treatment for type 2 DM with non-insulin
             oral or injectable agents

          -  Non-DM group with similar age range as the DM group, non-diabetic fasting plasma
             glucose (&lt;126 mg/dL) and hemoglobin A1c (HbA1c) (&lt;6.5%)

          -  Participants capable of providing informed consent

        Exclusion Criteria:

          -  Type 2 DM treated wiyh insulin (as of 9/25/2017)

          -  Type 1 DM

          -  Intolerance to insulin

          -  History of severe hypoglycemia

          -  Participants who have &gt;1 asymptomatic and/or symptomatic episode of hypoglycemia
             (glucose &lt; 70 mg/dL) during finger stick or plasma glucose

          -  Acute medical condition that required either hospitalization or surgery within the
             past 6 months (e.g., severe hypoglycemia, malignancies, myocardial infarction,stroke)

          -  Liver or renal failure or transplant

          -  Dementia (Mini Mental State Examination [MMSE] scores â‰¤20)

          -  Current recreational drug or alcohol abuse

          -  Serious systemic disease that would interfere with conduction of clinical trial (mild
             forms of neurological conditions e.g. Parkinson's Disease, autonomic neuropathy etc.
             would be allowed)

          -  Magnetic Resonance Imaging (MRI) substudy in 40 DM patients only: claustrophobia and
             implants incompatible with 3-Tesla MRI

          -  Safety substudy in 20 IDDM patients only: Insulin-treated type 2 diabetics with a
             C-peptide of &lt;0.8 ng/mLd and fasting blood glucose &gt;150 mg/dL will be excluded even
             without history of hypoglycemia during finger stick measurements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vera Novak, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Novak, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Gavrieli</last_name>
    <phone>617-632-8859</phone>
    <email>agavriel@bidmc.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Freddy J Alfaro</last_name>
    <phone>617-632-8883</phone>
    <email>falfarom@bidmc.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Gavrieli, PhD</last_name>
      <phone>617-632-8859</phone>
      <email>safelab@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Freddy J Alfaro, MD</last_name>
      <phone>6176328883</phone>
      <email>safelab@bidmc.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Novak, MD PhD</last_name>
      <phone>617-424-4101</phone>
      <email>PNOVAK2@PARTNERS.ORG</email>
    </contact>
    <contact_backup>
      <last_name>Freddy J Alfaro</last_name>
      <phone>617-525-3161</phone>
      <email>falfarom@bidmc.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lioutas VA, Alfaro-Martinez F, Bedoya F, Chung CC, Pimentel DA, Novak V. Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke. Transl Stroke Res. 2015 Aug;6(4):264-75. doi: 10.1007/s12975-015-0409-7. Epub 2015 Jun 5. Review.</citation>
    <PMID>26040423</PMID>
  </reference>
  <reference>
    <citation>Lioutas VA, Novak V. Intranasal insulin neuroprotection in ischemic stroke. Neural Regen Res. 2016 Mar;11(3):400-1. doi: 10.4103/1673-5374.179040.</citation>
    <PMID>27127468</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2015</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Vera Novak</investigator_full_name>
    <investigator_title>Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Intranasal Insulin</keyword>
  <keyword>Placebo</keyword>
  <keyword>Memory</keyword>
  <keyword>Gait</keyword>
  <keyword>Non diabetic older controls</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>BWH's site data will be shared with BIDMC site upon BWH's site recruitment initiation</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

